Zymeworks Inc. has pursued a strategy of funding its internal development of bispecific antibody therapies for cancer by licensing non-exclusive rights to its technology platforms with six partners now, dating back to 2011, but the $50m upfront payment it is getting from Janssen Biotech Inc. in a deal announced Nov. 13 exceeds the aggregate upfront cash it received up front in its previous deals.
In outlining the six-target licensing agreement around its Azymetric and EFECT (Effector Function and Enhancement Control Technology) platforms with the...








